Trading Signals: HTBX Stock Price Prediction and Forecast (Mon. Dec. 28, 2015 - Mon. May. 2, 2022)(Heat Biologics, Inc.)
| HTBX latest price $8.7500 (1.63%) ($8.1900 - $8.8200) on Thu. Apr. 4, 2019. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 5.29% (three month average) | RSI | 52 | Latest Price | $8.7500(1.63%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | HTBX declines -0.1% a day on average for past five trading days. | Weekly Trend | HTBX declines -1% a week on average for past two weeks. | Market Behavior | Value stock rally for large cap. Value stock rally for small cap. | Correlated ETFs | Broad market will support HTBX advance at 0% a week (0% probability) GDX(11%) IGOV(11%) GDXJ(10%) GLD(10%) MCHI(9%) | Factors Impacting HTBX price | HTBX will decline at least -2.645% in a week (0% probabilities). VCSH(-10%) UUP(-5%) JETS(-5%) CEMB(-5%) IFRA(-3%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.645% (StdDev 5.29%) | Hourly BBV | 0 () | Intraday Trend | 3.3% | | | |
|
5 Day Moving Average | $8.71(0.46%) | 10 Day Moving Average | $8.68(0.81%) | 20 Day Moving Average | $8.72(0.34%) | To recent high | -27.7% | To recent low | 16.8% | Market Cap | $963m | | | | Heat Biologics, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the company's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Morrisville, NC. |